Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q3 2024 vs. Q2 2024
How the institutions holding Lakefront Biotherapeutics NV changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 85 | 1 | 79 | −5 |
| Shares | 19.9M | 560.4K | 13.7M | −5.71M (−29.5%) |
| Value | $494.0M | $13.9M | $393.4M | −$86.8M (−18.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 800,000 | $23.0M | 2.58% |
| BlackRock, Inc. | 504,266 | $14.5M | 0.00% |
| Crossmark Global Holdings, Inc. | 37,386 | $1.08M | 0.02% |
| HRT Financial LP | 16,241 | $467.0K | 0.00% |
| QRG Capital Management, Inc. | 8,589 | $247.3K | 0.00% |
| Barclays PLC | 100 | $2.88K | 0.00% |
| Planned Solutions, Inc. | 100 | $2.88K | 0.00% |
| Bryn Mawr Trust Co | 74 | $2.13K | 0.00% |
| SRS Capital Advisors, Inc. | 40 | $1.15K | 0.00% |
| Jaffetilchin Investment Partners, LLC | 5 | $144 | 0.00% |
| Hexagon Capital Partners LLC | 5 | $144 | 0.00% |
Sold out (16)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Wellington Management Group LLP | 345,050 | $8.55M |
| Susquehanna International Group, LLP | 30,842 | $764.3K |
| Dimensional Fund Advisors LP | 28,774 | $713.0K |
| Campbell & CO Investment Adviser LLC | 19,883 | $492.7K |
| D. E. Shaw & Co., Inc. | 16,780 | $415.8K |
| Old Mission Capital LLC | 14,124 | $350.0K |
| Marshall Wace, LLP | 12,715 | $315.1K |
| Simplex Trading, LLC | 9,178 | $227.0K |
| Aquatic Capital Management LLC | 5,800 | $143.7K |
| Group One Trading, L.P. | 2,100 | $52.0K |
| Acadian Asset Management LLC | 844 | $20.0K |
| New York State Common Retirement Fund | 640 | $15.9K |
| Farther Finance Advisors, LLC | 77 | $1.93K |
| RFP Financial Group LLC | 68 | $1.69K |
| CIBC Private Wealth Group, LLC | 11 | $283 |
| Lazard Asset Management LLC | 5 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 560,358 | $13.9M |